Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
58.32
+0.35 (0.60%)
Oct 8, 2025, 3:45 PM EDT - Market open
Hims & Hers Health Stock Forecast
Stock Price Forecast
The 10 analysts that cover Hims & Hers Health stock have a consensus rating of "Hold" and an average price target of $37.2, which forecasts a -36.21% decrease in the stock price over the next year. The lowest target is $26 and the highest is $68.
Price Target: $37.2 (-36.21%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Hims & Hers Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 7 | 6 | 7 | 7 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 12 | 12 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $68 | Strong Buy | Maintains | $68 | +16.60% | Sep 12, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $48 → $37 | Hold | Maintains | $48 → $37 | -36.56% | Aug 18, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 5, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $45 → $48 | Hold | Maintains | $45 → $48 | -17.70% | Jul 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $40 | Hold | Reiterates | $40 | -31.41% | Jun 11, 2025 |
Financial Forecast
Revenue This Year
2.39B
from 1.48B
Increased by 61.66%
Revenue Next Year
2.85B
from 2.39B
Increased by 19.48%
EPS This Year
0.62
from 0.53
Increased by 15.95%
EPS Next Year
0.84
from 0.62
Increased by 35.54%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5B | 3.2B | |||
| Avg | 2.4B | 2.9B | |||
| Low | 2.3B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.1% | 32.0% | |||
| Avg | 61.7% | 19.5% | |||
| Low | 52.7% | 2.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.76 | 1.50 | |
| Avg | 0.62 | 0.84 | |
| Low | 0.41 | 0.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 42.0% | 143.3% | |
| Avg | 15.9% | 35.5% | |
| Low | -22.7% | -36.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.